Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genetic SignaturesASX:GSS -1.49% Cash Ratio is 6.25 as of Dec. 2025, which is 13% below its 10-year median of 7.20. The stock has 4 warning signs investors should review. Among 208 Medical Diagnostics & Research companies, Genetic Signatures ranks better than 92.79% on this metric.
Genetic Signatures has a Cash Ratio of 6.25. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Genetic Signatures's Cash Ratio or its related term are showing as below:
ASX:GSS'
s Cash Ratio Range Over the Past 10 Years
Min: 1.3 Med: 7.2 Max: 23.11
Current: 6.25
During the past 11 years, Genetic Signatures's highest Cash Ratio was 23.11. The lowest was 1.30. And the median was 7.20.
ASX:GSS's Cash Ratio is ranked better than 92.79% of 208
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.965
vs ASX:GSS: 6.25
Genetic Signatures (ASX:GSS) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Genetic Signatures Cash Ratio Related Terms
Genetic Signatures Cash Ratio Historical Data
* Premium members only.
The historical data trend for Genetic Signatures's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Genetic Signatures's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genetic Signatures Cash Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Signatures's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Genetic Signatures's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genetic Signatures (ASX:GSS) has a Cash Ratio of 6.25 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Genetic Signatures and its competitors. This is 13% below median its historical median of 7.20. Over the past decade, Genetic Signatures' Cash Ratio has ranged from 1.30 to 23.11. According to the industry distribution chart, Genetic Signatures ranks #15 out of 208 companies in the Medical Diagnostics & Research industry, placing it in the top 7.2%.
Is Genetic Signatures' Cash Ratio too high?
Genetic Signatures' current Cash Ratio of 6.25 is 13% below median its 10-year median of 7.20. Over the past 10 years, this metric has ranged from a low of 1.30 to a high of 23.11. The Medical Diagnostics & Research industry median Cash Ratio is 0.97. Genetic Signatures' value of 6.25 is 547.7% above this industry median. Based on the distribution chart, Genetic Signatures ranks #15 out of 208 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does Genetic Signatures' Cash Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Genetic Signatures ranks #15 out of 208 companies for Cash Ratio. This places Genetic Signatures in the top 7% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 0.97. Genetic Signatures' value of 6.25 is 547.7% above this benchmark. Historically, Genetic Signatures' own Cash Ratio has ranged from 1.30 to 23.11 over the past decade. While the company's 10-year median is 7.20 vs. the industry median of 0.97, Genetic Signatures has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Diagnostics & Research company?
The median Cash Ratio among Medical Diagnostics & Research companies is 0.97, based on 208 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genetic Signatures's current Cash Ratio of 6.25 is 547.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Genetic Signatures and its competitors. For the Medical Diagnostics & Research industry, the median Cash Ratio is 0.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genetic Signatures's current Cash Ratio is 6.25, which is 13% below median its own 10-year median of 7.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Signatures stock overvalued right now?
Based on GuruFocus' analysis, Genetic Signatures (ASX:GSS) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.38, compared to a current price of A$0.07 — trading 82.6% below its estimated fair value. The current Cash Ratio is 6.25, which is 13% below median its 10-year median of 7.20 and 547.7% above the Medical Diagnostics & Research industry median of 0.97. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Genetic Signatures (ASX:GSS), the current Cash Ratio is 6.25 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Genetic Signatures Ltd is a specialist molecular diagnostics company, specializing in syndromic multiplex real-time PCR testing. The company offers products for the routine detection of infectious diseases and pathogens. It has three operating segments based on regions: Asia Pacific, EMEA, and Americas. It generates the majority of its revenue from the Asia Pacific region. The group's operations are based in Australia, with sales and support teams in the UK, Germany, and the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:GSS has been successfully added to your 
